Association of the YTHDF2 rs3738067 A>G variant with hepatoblastoma risk: a multicenter case-control study in Chinese children Authors: Zhuo Wang, Jinhong Zhu, Wenli Zhang, Zhonghua Yang, Yong Li, Li Li, Suhong Li, Jiwen Cheng, Jiao Zhang, Jing He, Peng Yi Published: 2025 ABSTRACT AbstractBackgroundAs a rare cancer, hepatoblastoma is the most prevalent malignant liver tumor in children, yet its underlying causes are poorly understood. YTHDF2, a canonical m⁶A reader, regulates mRNA stability and decay, and its dysregulation has been implicated in tumorigenesis across multiple malignancies. Whether YTHDF2 polymorphisms influence hepatoblastoma risk is unclear. This multicenter case-control study was therefore designed to analyze the YTHDF2 rs3738067 A > G variant in Chinese children.MethodsWe recruited 313 hepatoblastoma cases and 1446 controls from seven hospitals across China for this case-control study. The YTHDF2 rs3738067 A > G polymorphism was genotyped using the TaqMan PCR method. We assessed its association with hepatoblastoma risk using multivariate logistic regression to calculate adjusted odds ratios and 95% confidence intervals, controlling for age and sex.ResultsComprehensive analyses of this multi-center Chinese pediatric cohort revealed that the YTHDF2 rs3738067 A > G polymorphism was not associated with hepatoblastoma risk in any analysis, including the overall population and all stratified subgroups.ConclusionsThese findings suggest that this specific YTHDF2 variant may not be a key risk factor for hepatoblastoma in Chinese children. Future studies incorporating diverse ethnic populations and investigating other polymorphisms, alone or in combination, are warranted to confirm these findings and explore potential associations.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15478-x.Keywords: Hepatoblastoma, YTHDF2, Polymorphism, Susceptibility Introduction As the most frequently diagnosed hepatic malignancy in early childhood, hepatoblastoma primarily presents in children under the age of 2 [1]. As a rare pediatric tumor (annual incidence: 1.5 per million), hepatoblastoma constitutes about 1% of all pediatric cancers [2, 3]. It is an embryonic tumor that arises from epithelial hepatocyte precursors [4]. With the current treatment protocols, the overall survival of patients with hepatoblastoma is 70%−80% [5, 6]. Hepatoblastoma typically presents with subtle or absent early symptoms; the predominant initial manifestation is a rapidly enlarging, non-tender abdominal mass, which represents the chief complaint in > 80% of cases [7]. Additional clinical features may include irritability, feeding difficulties, anorexia, emesis, dehydration, and abdominal pain. Severe cases can lead to anemia, jaundice, or hypovolemic shock secondary to tumor rupture [8]. The alpha fetoprotein (AFP) level serves as a key biomarker, being increased in 90% of patients. Radiologic tests such as abdominal ultrasonography, intravenous contrast-enhanced computed tomography, and MRI also help improve precision in diagnosis [9, 10]. Multimodal therapy combining neoadjuvant chemotherapy, surgical resection (or liver transplantation for unresectable cases), and risk stratification via systems such as PRETEXT or SEER-based nomograms has increased 5-year survival rates to > 80% for early-stage hepatoblastoma patients [3]. However, metastatic disease remains challenging with significantly poorer outcomes, and survivorship programs address long-term quality-of-life issues in cured patients. Adult hepatocellular carcinoma (HCC) is related mainly to hepatitis B/C, alcohol, or nonalcoholic steatohepatitis (NASH), whereas hepatoblastoma has no such associations [11]. The etiology of hepatoblastoma remains unknown [3]. Epidemiological studies have identified neonatal exposure to diagnostic radiation, therapeutic oxygen supplementation, specific pharmacotherapies (e.g., furosemide), and prolonged total parenteral nutrition (TPN) as significant environmental risk factors for hepatoblastoma development, particularly in preterm infants with extended stays in the neonatal intensive care unit [4]. Prematurity and very low birth weight may also contribute to hepatoblastoma risk [3, 7]. While most cases are sporadic, several genetic syndromes confer a predisposition to hepatoblastoma, including Beckwith–Wiedemann syndrome, familial adenomatous polyposis (FAP), and trisomy 18. A functional role in the pathogenesis of hepatoblastoma has been identified for chromosomes 5, 11, and 18. Additionally, hereditary adenomatous polyposis and Down syndrome are associated with hepatoblastoma [12]. Single nucleotide polymorphisms (SNPs) have been implicated as predisposing factors for hepatoblastoma in epidemiological studies [13–17]. Identifying novel hepatoblastoma susceptibility variants may facilitate risk stratification, reduce disease onset in vulnerable children via tailored prevention strategies (e.g., medications, lifestyle changes), and improve early detection. YT521-B homology (YTH) domain family 2 (YTHDF2), an N6-methyladenosine (m⁶A)-specific RNA-binding protein, recognizes m⁶A modifications and mediates mRNA degradation through the mRNA decay machinery [18]. RNA m⁶A, first identified in Novikoff hepatoma cells [19], represents the most prevalent internal mRNA modification in eukaryotes. This epigenetic mark regulates cytoplasmic mRNA localization, stability, and translational efficiency, profoundly influencing gene expression programs [20]. During oncogenesis, YTHDF2 drives hepatocellular carcinoma progression via m⁶A-dependent SOCS2 transcript destabilization [21]. Emerging evidence suggests that m6A RNA modification plays an oncogenic role in hepatoblastoma. The m6A reader YTHDF2 is upregulated in hepatoblastoma and serves as a predictor of poor prognosis. It promotes hepatoblastoma progression specifically by regulating the oncogenic Wnt/β-catenin signaling pathway as part of a dysregulated m6A modification network [22]. Moreover, YTHDF2 promotes hepatoblastoma progression by mediating m6A-dependent degradation of LATS2 mRNA, thereby activating the YAP1/ATF4/PSAT1 axis to inhibit ferroptosis in tumor cells [23]. Additionally, it regulates hematopoietic stem cell homeostasis [24], impacts neural development by mediating m6A-dependent degradation of target mRNAs [25], and governs reproductive biology [26]. Moreover, YTHDF2 expression peaks in proliferating tissues and reproductive organs, with SNPs potentially influencing human longevity [27]. However, no studies have investigated the roles of YTHDF2 polymorphisms in hepatoblastoma. Therefore, we performed a first-tier evaluation of a carefully selected variant in the YTHDF2 gene (rs3738067) within a well-characterized Chinese hepatoblastoma cohort with 313 cases and 1446 controls from seven independent medical institutions before embarking on costly genome-wide studies or functional analyses. Methods Study participants We performed a multi-center case-control study enrolling 313 histopathologically confirmed hepatoblastoma cases and 1446 controls (Table S1). All participants were aged < 14 years and were recruited from seven independent Chinese hospitals as described previously [14–16]. This multicenter case-control study enrolled 313 children with hepatoblastoma and 1466 healthy controls. All cases were newly diagnosed, biopsy-confirmed, and treatment-naive at enrollment. Participants were recruited from seven major medical centers located in Guangdong, Henan, Shaanxi, Liaoning, Hunan, Shannxi, and Kunming provinces. Clinical staging for hepatoblastoma was determined using the PRETEXT (Pretreatment Extent of Disease) classification system [3]. The control group consisted of healthy children, who were frequency-matched to the cases at the group level by age and sex. The recruitment aimed for a comparable distribution of these variables between groups, resulting in an overall case-to-control ratio between 1:4 and 1:5. This was achieved by enrolling control subjects from the same hospitals during the same period, with their age categorized to approximate the distribution observed in the case cohort. Inclusion criteria for controls were: (1) no personal history of malignancy; and (2) no clinical evidence of liver or systemic disease. Exclusion criteria included: (1) a family history of cancer in first- or second-degree relatives; (2) any known genetic syndrome or congenital anomaly; and (3) biological relatedness to any enrolled hepatoblastoma patient. Written informed consent was obtained from the parents or guardians of all participants before enrollment, in accordance with the Declaration of Helsinki. Ethical approval was granted by the institutional review boards in the Guangzhou Women and Children’s Medical Center (Approval No: 202016600). SNP selection and genotyping We identified potentially functional SNPs in the YTHDF2 gene from the dbSNP database and the SNPinfo web server (http://snpinfo.niehs.nih.gov/). In brief, we selected candidate YTHDF2 SNPs from the 5’ flanking, 5’ untranslated region (UTR), 3’ UTR, and exonic regions based on two criteria: a minor allele frequency (MAF) > 0.05 in East Asian populations (1000 Genomes) and predicted potential function by SNPinfo. The full selection methodology followed our prior protocols [28, 29]. Briefly, four YTHDF2 gene SNPs, rs33914074, rs12068075, rs3753692, and rs3738067, were retrieved after the initial screen. These variants were sequentially filtered based on the following criteria: (1) Predicted functional relevance using the SNPinfo web server, which led to the exclusion of rs33914074; and (2) MAF > 0.05 in East Asian populations (1000 Genomes Project), resulting in the exclusion of rs12068075. The two remaining SNPs, rs3753692 and rs3738067, were found to be in perfect linkage disequilibrium (R²=1.00) in East Asians. Given this complete redundancy, only one required genotyping. We selected rs3738067 for final analysis because it is located within the 5’ UTR, a region with a stronger possibility of influencing mRNA regulation compared to the 5’ near-gene location of rs3753692. Genomic DNA from peripheral blood was further genotyped with the TaqMan assay on an Applied Biosystems real-time PCR system, with 10% duplicates and negative controls per plate. Assay validation confirmed 100% concordance in duplicate samples [28]. Statistical analysis We employed the independent samples t-test for age and the χ² test for sex and genotype frequencies to compare cases and controls. A chi-square goodness-of-fit test verified Hardy-Weinberg equilibrium (HWE) in control subjects. To determine the association between YTHDF2 rs3738067 A > G and hepatoblastoma risk, we performed unconditional multivariable logistic regression, adjusting for age and sex, to estimate adjusted odds ratios (AORs) and their 95% confidence intervals (CIs). The genotype-phenotype association was assessed through additive, dominant, and recessive genetic models. We also carried out stratification analysis based on age, sex, and clinical stage of the hepatoblastoma cases. All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, United States), with a two-sided significance threshold of P < 0.05. Results YTHDF2 rs3738067 A>G polymorphism and hepatoblastoma susceptibility The age, sex, and clinical features of the study cohort (313 cases and 1446 controls) are detailed in Table S1. Successful genotyping rates exceeded 99% (310 cases/1444 controls), with the YTHDF2 rs3738067 genotype distribution conforming to HWE in controls (P = 0.612), confirming minimal genotyping error or population stratification bias. As presented in Table 1, the rs3738067 polymorphism demonstrated comparable genotypic frequencies between hepatoblastoma patients and controls: AA (cases: 53.87% vs. controls: 54.09%), AG (38.06% vs. 39.27%), and GG (8.06% vs. 6.65%). Multivariable logistic regression with adjustment for age and sex revealed null associations of rs3738067 with hepatoblastoma susceptibility under additive (AOR = 1.04, 95% CI = 0.86–1.27, P = 0.681), dominant (AOR = 1.01, 95% CI = 0.79–1.29, P = 0.958), or recessive (AOR = 1.24, 95% CI = 0.78–1.96, P = 0.365) models. Table 1Association between YTHDF2 rs3738067 A > G polymorphism and hepatoblastoma susceptibilityGenotypeCases(N = 310)Controls(N = 1444)P aCrude OR(95% CI) P Adjusted OR(95% CI) bP brs3738067 (HWE = 0.612) AA167 (53.87)781 (54.09)1.001.00 AG118 (38.06)567 (39.27)0.97 (0.75–1.26)0.8380.97 (0.75–1.26)0.822 GG25 (8.06)96 (6.65)1.22 (0.76–1.95)0.4121.22 (0.76–1.96)0.407 Additive0.6751.04 (0.86–1.27)0.6751.04 (0.86–1.27)0.681 Dominant143 (46.13)663 (45.91)0.9451.01 (0.79–1.29)0.9451.01 (0.79–1.29)0.958 Recessive285 (91.94)1348 (93.35)0.3721.23 (0.78–1.95)0.3731.24 (0.78–1.96)0.365OR odds ratio, CI confidence interval, HWE Hardy-Weinberg equilibriuma x2 test for genotype distributions between hepatoblastoma patients and controlsbAdjusted for age and gender Association between YTHDF2 rs3738067 A > G polymorphism and hepatoblastoma susceptibility OR odds ratio, CI confidence interval, HWE Hardy-Weinberg equilibrium a x2 test for genotype distributions between hepatoblastoma patients and controls bAdjusted for age and gender Stratification analysis for the YTHDF2 rs3738067 A>G with hepatoblastoma risk This null association remained consistent across all subgroups, regardless of age (< 17 vs. ≥17 months), sex, and clinical stage (stage I/II vs. III/IV) (Table 2). Table 2Stratification analysis for the association between YTHDF2 rs3738067 A > G polymorphism and hepatoblastoma riskVariablesAAAG/GGCrude OR P Adjusted OR aP a(Cases/Controls)(95% CI)(95% CI)Age, month < 1789/33676/3050.94 (0.67–1.33)0.7270.95 (0.67–1.34)0.764 ≥ 1778/44567/3581.07 (0.75–1.52)0.7171.08 (0.76–1.55)0.658Gender Females74/33153/2640.90 (0.61–1.32)0.5870.90 (0.61–1.32)0.576 Males93/45090/3991.09 (0.79–1.50)0.5921.10 (0.80–1.52)0.545Clinical stage I + II82/78178/6631.12 (0.81–1.55)0.4951.12 (0.81–1.55)0.498 III + IV53/78136/6630.80 (0.52–1.24)0.3160.80 (0.52–1.23)0.310OR odds ratio, CI confidence intervalaAdjusted for age and gender, omitting the corresponding stratify factor Stratification analysis for the association between YTHDF2 rs3738067 A > G polymorphism and hepatoblastoma risk OR odds ratio, CI confidence interval aAdjusted for age and gender, omitting the corresponding stratify factor Discussion This multi-center case-control study, with a rigorous epidemiological design and adequate statistical power, demonstrated no association of the YTHDF2 rs3738067 A > G SNP with hepatoblastoma risk for Chinese children. These consistent null findings across genetic models and stratified subgroups provide high-confidence evidence that this variant does not contribute substantially to hepatoblastoma pathogenesis in this population.YTHDF2 serves as a prototypical m⁶A reader protein involved in RNA m6A-associated metabolism [30], an evolutionarily conserved epitranscriptomic modification [31]. RNA m6A spans prokaryotes to eukaryotes as the most abundant internal mRNA mark [30, 32–34]. m6A is enriched near transcription start sites, aiding nucleosome positioning and transcription initiation in eukaryotes [30]. It is also found to prevalent in human exons, with reduced levels linked to cancer [35]. Mechanistically, YTHDF2 selectively binds m⁶A-modified mRNAs via its YTH domain and controls RNA decay [36]. It recruits the CCR4-NOT deadenylase complex by binding the SH domain of CNOT1, leading to degradation of m6A-modified RNAs and regulation of mRNA stability and translation [37, 38]. Therefore, YTHDF2 could function as a context-dependent oncogenic modulator by regulating both tumor promoter and suppressor gene mRNAs. In acute myeloid leukemia, it differentially degrades tumor suppressors in leukemic stem cells [24, 39]. In solid tumors, YTHDF2 drives HCC progression [40, 41]. Moreover, YTHDF2 promotes proliferation/migration in prostate [42] and bladder [43] cancers via m⁶A-dependent pathways. Given the established oncogenic functions of YTHDF2 across malignancies, we hypothesized that functional YTHDF2 polymorphisms could modulate hepatoblastoma susceptibility, which is supported by emerging evidence linking YTHDF2 variants to colorectal cancer risk [44]. However, in contrast to our hypothesis, rigorous multivariable analyses revealed no significant associations between rs3738067 and hepatoblastoma risk. This well-powered null finding provides high-confidence evidence that YTHDF2 rs3738067 is not a major susceptibility locus for hepatoblastoma in Chinese children. YTHDF2 is a well-established promoter of HCC progression; however, the relationship between the rs3738067 A > G polymorphism and HCC susceptibility remains unreported and unclear. While a pediatric hepatoblastoma study showed no association, this does not inform HCC risk due to fundamental differences between the two cancers, including etiologies, molecular drivers, and age distributions. Future studies are needed to determine whether rs3738067 or other YTHDF2 variants contribute to HCC genetic predisposition. Moreover, the lack of a significant association between the YTHDF2 rs3738067 A > G variant and hepatoblastoma risk in our study invokes consideration of tumor-type specificity. Our prior research on this same SNP in other pediatric solid tumors reveals a complex picture: it conferred a decreased risk for neuroblastoma [45], an increased risk for glioma [29], and showed no effect on Wilms tumor risk [46]. This pattern suggests that the functional consequence of rs3738067 is not universal but is highly context-dependent, likely influenced by the cell of origin, developmental timing, and distinct oncogenic pathways active in each tumor type. Hepatoblastoma, an embryonal liver tumor driven by Wnt/β-catenin pathway dysregulation, may represent another tumor type where this variant does not play a measurable role in susceptibility. Therefore, our current negative result, consistent with its null effect in Wilms tumor, refines the understanding of YTHDF2’s role in oncogenesis. As a multifactorial malignancy, hepatoblastoma pathogenesis involves complex interactions between genetic susceptibility and environmental exposures. While this study provides robust epidemiological evidence regarding YTHDF2 rs3738067, several limitations warrant consideration. First, while we adjusted for age and sex, we were unable to account for other potential confounders such as socioeconomic status, birth weight, prematurity, or maternal factors, family history, prenatal exposure, dietary patterns, and environmental toxins due to the lack of systematic data on these variables in our clinic-based archives. Although our study design (recruiting controls from the same hospitals as cases) helps mitigate some selection biases, residual confounding from unmeasured factors cannot be entirely ruled out. Future studies integrating detailed epidemiological questionnaires with genetic data are warranted to explore gene-environment interactions. Second, selection bias is another potentially inevitable factor. Despite the use of multicenter recruitment, controls may not fully represent population genetic diversity because of the hospital-based design. Third, more samples should be recruited to increase the statistical power and the credibility of the conclusions. Fourth, only one polymorphism of the YTHDF2 gene was evaluated. A comprehensive assessment of YTHDF2 haplotypes and functional SNPs (e.g., promoter/enhancer variants) is needed. Therefore, to better dissect the contributions of the YTHDF2 SNP in hepatoblastoma risk, investigations should establish prospective birth cohorts integrating environmental monitoring and genomic profiling, develop polygenic risk scores incorporating m⁶A pathway genes, and perform mechanistic validation. Finally, as all participants were of Chinese descent, the generalizability of our findings to other ethnic populations may be limited due to potential variations in genetic architecture (e.g., genetic background and allele frequencies) and environmental risk factors. Future studies in diverse ethnic cohorts are warranted to validate our results. Despite its limitations, this well-powered multi-center study provides the most comprehensive epidemiological assessment to date of YTHDF2 rs3738067 A > G in Chinese patients with pediatric hepatoblastoma. Our robust null findings, which are consistent across genetic models and stratified analyses, provide high-confidence evidence that this specific polymorphism does not significantly contribute to hepatoblastoma susceptibility. This conclusion redirects investigative focus to unannotated functional variants in YTHDF2 regulatory regions, alternative genetic mechanisms (e.g., METTL3 methylation writers), and gene‒environment interactions. Conclusion In summary, this study suggests that YTHDF2 rs3738067 A > G is not a major susceptibility locus for hepatoblastoma in Chinese children. More research should validate findings across diverse ethnic cohorts to confirm population-specific effects and develop integrated risk models combining genetic, epigenetic, and environmental factors. Such advances will elucidate hepatoblastoma pathogenesis and facilitate precision prevention strategies for high-risk infants. Supplementary Information Supplementary Material 1. Acknowledgements Not applicable. Clinical trial number Not applicable. Abbreviations Alpha fetoprotein Hepatocellular carcinoma Nonalcoholic steatohepatitis Total parenteral nutrition Familial adenomatous polyposis Single nucleotide polymorphism N6-methyladenosine YT521-B homology Hardy-Weinberg equilibrium Adjusted odds ratio Confidence interval Authors’ contributions All the authors contributed significantly to this work. Zhonghua Yang, Yong Li, Li Li, Suhong Li, Jiwen Cheng, Jiao Zhang, and Jing He performed the research study and collected the samples and information; Wenli Zhang and Jing He analyzed the data; Peng Yi and Jing He designed the research study and supervised the project; Zhuo Wang, Jinhong Zhu, Wenli Zhang, Peng Yi and Jing He wrote the paper; Wenli Zhang and Jing He prepared all the tables. All the authors reviewed the manuscript. In addition, all the authors have read and approved the final version of manuscript. Funding This study was supported by grants from the Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (No: 2019B030301004). Data availability The original contributions presented in the study are provided in the article or Supplementary Materials; all the data are available upon request from the correspondence authors (Peng Yi or Jing He). Declarations Ethics approval and consent to participate This study was approved by the Institutional Review Board of Guangzhou Women and Children’s Medical Center (Approval No: 202016600). The research was aligned with the ethical standards set forth by the Declaration of Helsinki. All participants’ parents or legal guardians provided written informed consent before enrollment. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Zhuo Wang, Jinhong Zhu and Wenli Zhang contributed equally to this work. Contributor Information Jing He, Email: hejing198374@gmail.com. Peng Yi, Email: yipengqz@163.com. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The original contributions presented in the study are provided in the article or Supplementary Materials; all the data are available upon request from the correspondence authors (Peng Yi or Jing He).